Katsanis E - Search Results

1

Pak2 regulates myeloid-derived suppressor cell development in mice.

Zeng Y, Hahn S, Stokes J, Hoffman EA, Schmelz M, Proytcheva M, Chernoff J, Katsanis E. Zeng Y, et al. Among authors: katsanis e. Blood Adv. 2017 Oct 10;1(22):1923-1933. doi: 10.1182/bloodadvances.2017007435. eCollection 2017 Oct 10. Blood Adv. 2017. PMID: 29296839 Free PMC article.

2

Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice.

He L, Feng H, Raymond A, Kreeger M, Zeng Y, Graner M, Whitesell L, Katsanis E. He L, et al. Among authors: katsanis e. Cancer Immunol Immunother. 2001 Mar;50(1):31-40. doi: 10.1007/pl00006680. Cancer Immunol Immunother. 2001. PMID: 11315508 Free PMC article.

3

Stressed apoptotic tumor cells express heat shock proteins and elicit tumor-specific immunity.

Feng H, Zeng Y, Whitesell L, Katsanis E. Feng H, et al. Among authors: katsanis e. Blood. 2001 Jun 1;97(11):3505-12. doi: 10.1182/blood.v97.11.3505. Blood. 2001. PMID: 11369644 Free article.

4

Stressed apoptotic tumor cells stimulate dendritic cells and induce specific cytotoxic T cells.

Feng H, Zeng Y, Graner MW, Katsanis E. Feng H, et al. Among authors: katsanis e. Blood. 2002 Dec 1;100(12):4108-15. doi: 10.1182/blood-2002-05-1389. Epub 2002 Jul 25. Blood. 2002. PMID: 12393401 Free article.

5

Exogenous stress proteins enhance the immunogenicity of apoptotic tumor cells and stimulate antitumor immunity.

Feng H, Zeng Y, Graner MW, Likhacheva A, Katsanis E. Feng H, et al. Among authors: katsanis e. Blood. 2003 Jan 1;101(1):245-52. doi: 10.1182/blood-2002-05-1580. Epub 2002 Aug 22. Blood. 2003. PMID: 12393411 Free article.

6

Tumor-derived, chaperone-rich cell lysate activates dendritic cells and elicits potent antitumor immunity.

Zeng Y, Feng H, Graner MW, Katsanis E. Zeng Y, et al. Among authors: katsanis e. Blood. 2003 Jun 1;101(11):4485-91. doi: 10.1182/blood-2002-10-3108. Epub 2003 Feb 6. Blood. 2003. PMID: 12576309 Free article.

7

Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers.

Graner MW, Zeng Y, Feng H, Katsanis E. Graner MW, et al. Among authors: katsanis e. Cancer Immunol Immunother. 2003 Apr;52(4):226-34. doi: 10.1007/s00262-002-0359-2. Epub 2003 Feb 18. Cancer Immunol Immunother. 2003. PMID: 12669247 Free PMC article.

8

Imatinib mesylate effectively combines with chaperone-rich cell lysate-loaded dendritic cells to treat bcr-abl+ murine leukemia.

Zeng Y, Graner MW, Feng H, Li G, Katsanis E. Zeng Y, et al. Among authors: katsanis e. Int J Cancer. 2004 Jun 10;110(2):251-9. doi: 10.1002/ijc.20115. Int J Cancer. 2004. PMID: 15069690

9

Induction of BCR-ABL-specific immunity following vaccination with chaperone-rich cell lysates derived from BCR-ABL+ tumor cells.

Zeng Y, Graner MW, Thompson S, Marron M, Katsanis E. Zeng Y, et al. Among authors: katsanis e. Blood. 2005 Mar 1;105(5):2016-22. doi: 10.1182/blood-2004-05-1915. Epub 2004 Sep 16. Blood. 2005. PMID: 15374884 Free PMC article.

10

Chaperone-rich cell lysates, immune activation and tumor vaccination.

Zeng Y, Graner MW, Katsanis E. Zeng Y, et al. Among authors: katsanis e. Cancer Immunol Immunother. 2006 Mar;55(3):329-38. doi: 10.1007/s00262-005-0694-1. Epub 2005 May 11. Cancer Immunol Immunother. 2006. PMID: 15887013 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

157 results

Search Page

Filters